196 related articles for article (PubMed ID: 18176866)
1. Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti-gad antibodies.
Vianello M; Bisson G; Dal Maschio M; Vassanelli S; Girardi S; Mucignat C; Fountzoulas K; Giometto B
Autoimmunity; 2008 Feb; 41(1):66-73. PubMed ID: 18176866
[TBL] [Abstract][Full Text] [Related]
2. Peculiar labeling of cultured hippocampal neurons by different sera harboring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab).
Vianello M; Giometto B; Vassanelli S; Canato M; Betterle C; Mucignat C
Exp Neurol; 2006 Dec; 202(2):514-8. PubMed ID: 16890938
[TBL] [Abstract][Full Text] [Related]
3. Glutamic acid decarboxylase autoantibodies and neurological disorders.
Vianello M; Tavolato B; Giometto B
Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
[TBL] [Abstract][Full Text] [Related]
4. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases.
Manto MU; Laute MA; Aguera M; Rogemond V; Pandolfo M; Honnorat J
Ann Neurol; 2007 Jun; 61(6):544-51. PubMed ID: 17600364
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome.
Dinkel K; Meinck HM; Jury KM; Karges W; Richter W
Ann Neurol; 1998 Aug; 44(2):194-201. PubMed ID: 9708541
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
7. [Islet beta cell function in latent autoimmune diabetes in adults with islet cell antibodies].
Yang L; Zhou ZG; Huang G; Yan X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 29(3):309-14. PubMed ID: 16136967
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic usefulness of glutamic acid decarboxylase antibodies in stiff-man syndrome].
Saiz A; Arias M; Fernández-Barreiro A; Mínguez A; Casamitjana R; Tolosa E; Graus F
Med Clin (Barc); 1998 Mar; 110(10):378-81. PubMed ID: 9567281
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection by estradiol: a role of aromatase against spine synapse loss after blockade of GABA(A) receptors.
Zhou L; Lehan N; Wehrenberg U; Disteldorf E; von Lossow R; Mares U; Jarry H; Rune GM
Exp Neurol; 2007 Jan; 203(1):72-81. PubMed ID: 17005180
[TBL] [Abstract][Full Text] [Related]
10. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus.
Bayreuther C; Hieronimus S; Ferrari P; Thomas P; Lebrun C
Diabetes Metab; 2008 Sep; 34(4 Pt 1):386-8. PubMed ID: 18583169
[TBL] [Abstract][Full Text] [Related]
11. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity.
Rakocevic G; Raju R; Dalakas MC
Arch Neurol; 2004 Jun; 61(6):902-4. PubMed ID: 15210528
[TBL] [Abstract][Full Text] [Related]
12. Alterations of GABA-mediated synaptic transmission in human epilepsy.
Lloyd KG; Bossi L; Morselli PL; Munari C; Rougier M; Loiseau H
Adv Neurol; 1986; 44():1033-44. PubMed ID: 3010675
[TBL] [Abstract][Full Text] [Related]
13. Diabetes affects the expression of GABA and potassium chloride cotransporter in the spinal cord: a study in streptozotocin diabetic rats.
Morgado C; Pinto-Ribeiro F; Tavares I
Neurosci Lett; 2008 Jun; 438(1):102-6. PubMed ID: 18457921
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies in autoimmune polyglandular syndrome type I patients react with major brain neurotransmitter systems.
Fetissov SO; Bensing S; Mulder J; Le Maitre E; Hulting AL; Harkany T; Ekwall O; Sköldberg F; Husebye ES; Perheentupa J; Rorsman F; Kämpe O; Hökfelt T
J Comp Neurol; 2009 Mar; 513(1):1-20. PubMed ID: 19107747
[TBL] [Abstract][Full Text] [Related]
15. Reversibility of cerebellar GABAergic synapse impairment induced by anti-glutamic acid decarboxylase autoantibodies.
Ishida K; Mitoma H; Mizusawa H
J Neurol Sci; 2008 Aug; 271(1-2):186-90. PubMed ID: 18534624
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients.
Errichiello L; Perruolo G; Pascarella A; Formisano P; Minetti C; Striano S; Zara F; Striano P
J Neuroimmunol; 2009 Jun; 211(1-2):120-3. PubMed ID: 19428124
[TBL] [Abstract][Full Text] [Related]
17. Serum antibodies in epilepsy and seizure-associated disorders.
McKnight K; Jiang Y; Hart Y; Cavey A; Wroe S; Blank M; Shoenfeld Y; Vincent A; Palace J; Lang B
Neurology; 2005 Dec; 65(11):1730-6. PubMed ID: 16344514
[TBL] [Abstract][Full Text] [Related]
18. [Steroid treatment in four cases of anti-GAD cerebellar ataxia].
Bonnan M; Cabre P; Olindo S; Signate A; Saint-Vil M; Smadja D
Rev Neurol (Paris); 2008 May; 164(5):427-33. PubMed ID: 18555874
[TBL] [Abstract][Full Text] [Related]
19. Effects of antisense glutamic acid decarboxylase oligodeoxynucleotide on epileptic rats induced by pentylenetetrazol.
He X; Wang W; Ruan X; Li W; Zhang L
Chin Med J (Engl); 2002 Mar; 115(3):425-9. PubMed ID: 11940381
[TBL] [Abstract][Full Text] [Related]
20. Anti-GAD antibodies and periodic alternating nystagmus.
Tilikete C; Vighetto A; Trouillas P; Honnorat J
Arch Neurol; 2005 Aug; 62(8):1300-3. PubMed ID: 16087772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
